No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Immune Thrombocytopenic Purpura (ITP) is a rare autoimmune disorder characterized by a low platelet count. Platelets are essential for normal blood clotting, and a low platelet count can lead to excessive bleeding. Treatment for ITP typically involves the use of hematological drugs, such as corticosteroids, intravenous immunoglobulin, and monoclonal antibodies. These drugs are used to reduce the destruction of platelets and to increase platelet production.
The ITP drug market is highly competitive, with a number of companies offering treatments for the disorder. These companies include Novartis, Pfizer, Amgen, and GlaxoSmithKline. Additionally, there are several biotechnology companies that are developing novel therapies for ITP, such as Karyopharm Therapeutics and Apellis Pharmaceuticals. These companies are focused on developing treatments that are more effective and have fewer side effects than existing therapies. Show Less Read more
